When James Thomson and his team succeeded in growing human embryonic stem cells in 1998, biology, health science and the biotech business sector began to fundamentally change. Today, at least 10 Wisconsin enterprises depend – in one way or another – on pluripotent stem cells, either human embryonic or induced pluripotent cells (iPS).